Fig. 2: In vivo efficacy of PF-332 against Beta SARS-CoV-2 (B.1.351) variant in Syrian hamsters.
a Design of the study. b Viral RNA levels in the lungs of control (vehicle-treated) and PF-332-treated (at 125 or 250 mg/kg, BID) SARS-CoV-2−infected hamsters at day 4 post-infection. Individual data and median values (indicated by bars) are presented and are expressed as log10 SARS-CoV-2 RNA copies per mg lung tissue. Data were analyzed with the Mann–Whitney U test (two-sided). ***P = 0.0007, ****P < 0.0001. c Infectious viral loads in the lungs of control (vehicle-treated) and PF-332-treated SARS-CoV-2-infected hamsters at day 4 pi (expressed as log10 TCID50 per mg lung tissue). Individual data and median values (indicated by bars) are presented. Data were analyzed with the Mann–Whitney U test (two-sided). *P = 0.034, ****P < 0.0001. d Weight change at day 4 pi in percentage, normalized to the body weight at the day of infection. Bars represent means ± SD. Data were analyzed with the Mann–Whitney U test (two-sided). **P = 0.0031, ***P = 0.0003. e Cumulative severity score from H&E stained slides of lungs from control (vehicle-treated) and PF-332-treated hamsters. Individual data and median values (indicated by bars) are presented and the dotted line represents the median score of untreated non-infected hamsters. Data were analyzed with the Mann–Whitney U test (two-sided). ****P < 0.0001. All data b–e are from two independent experiments with n = 12 for vehicle and 250 mg/kg BID groups and n = 10 for 125 mg/kg BID group. PF-332 = PF-07321332. Source data are provided as a Source Data file.
